Iloperidone (Fanapt) vs Risperidone (Risperdal)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Iloperidone (Fanapt)
Marketed by Vanda Pharmaceuticals
NCT00254202 · Phase 3 · completed
This 4-week, randomized, double-blind Phase 3 trial (Study 2 in the FANAPT label, n=604) compared iloperidone 24 mg/day with placebo and with ziprasidone as an active control in acute schizophrenia. The primary endpoint was change in PANSS total score at day 28. The FDA label states that iloperidone 24 mg/day was superior to placebo on this endpoint, so the primary was met; efficacy appeared similar to ziprasidone. Sources: CT.gov posted results and the FANAPT label (openFDA).
Next expected readout: November 2027 · NCT06961968 (registry estimate)
Reported efficacy
Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score (4 weeks): Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). (met)
Result source: NCT00254202
Risperidone (Risperdal)
Marketed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT04478838 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Iloperidone (Fanapt) | Risperidone (Risperdal) |
|---|---|---|
| PANSS total, change | -12 vs -7.1−4.9 vs placeboNCT002542021 other result
| -16.5 vs -9.2−7.2 vs placeboNCT021095621 other result
|
| CGI-S, change | —Trial running · NCT06961968 | -0.9 vs -0.5−0.4 vs placeboNCT021095621 other result
|
| PANSS response | —Trial running · NCT06961968 | —Not posted · NCT00297388 |
| PSP, change | —Trial running · NCT06961968 | —Not posted · NCT00297388 |
| Relapse (% of patients) | —Trial running · NCT06961968 | —Not posted · NCT00297388 |
PANSS total, change
- Iloperidone (Fanapt)
- -12 vs -7.1−4.9 vs placeboNCT00254202
1 other result
- 1.1 vs 12.4 NCT01291511
- Risperidone (Risperdal)
- -16.5 vs -9.2−7.2 vs placeboNCT02109562
1 other result
- -15.4 vs -9.2 NCT02109562
CGI-S, change
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Risperidone (Risperdal)
- -0.9 vs -0.5−0.4 vs placeboNCT02109562
1 other result
- -0.9 vs -0.5 NCT02109562
PANSS response
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Risperidone (Risperdal)
- —Not posted · NCT00297388
PSP, change
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Risperidone (Risperdal)
- —Not posted · NCT00297388
Relapse (% of patients)
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Risperidone (Risperdal)
- —Not posted · NCT00297388
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Iloperidone (Fanapt): 5 of 5 rows · Risperidone (Risperdal): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Iloperidone (Fanapt) | Risperidone (Risperdal) Rows use multiple source trials |
|---|---|---|
| Time to Relapse time to event · months | NA vs 3.25 placebo months @ 26wka,b,c,d NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 | 4.3 vs 3.71 Abilify months*a,b,c,d NCT00299702 · Phase 4 · registry result, not featured evidence · converted to months from 131 days as posted |
| Dropout rate | 34.6%e NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results51.3%Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 30.3%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 31.5%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence 18.8%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 12.5%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 13.3%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 6.7%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 6.7%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | 78.3%180 mg subcutaneousf NCT03978832 · Phase 4 · registry result, not featured evidence show 22 more results5.9%CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 0%CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 14.3%HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 5.9%HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 0% NCT01050582 · Phase 4 · registry result, not featured evidence 17.5% NCT01855074 · Phase 4 · registry result, not featured evidence 29.6% NCT00299702 · Phase 4 · registry result, not featured evidence 0%PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 0%PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 16.7% NCT00056498 · Phase 4 · registry result, not featured evidence 28.6%120 mg NCT02109562 · Phase 3 · registry result, not featured evidence 22.4%90 mg NCT02109562 · Phase 3 · registry result, not featured evidence —4 mg NCT04567524 · Phase 2 · registry result, not featured evidence 25%4 mg NCT04567524 · Phase 2 · registry result, not featured evidence —2 mg NCT04567524 · Phase 2 · registry result, not featured evidence 0%2 mg NCT04567524 · Phase 2 · registry result, not featured evidence 40%120 mg NCT01677377 · Phase 2 · registry result, not featured evidence 6.7%90 mg NCT01677377 · Phase 2 · registry result, not featured evidence 6.7%60 mg NCT01677377 · Phase 2 · registry result, not featured evidence 29.4%DLP-114 Alpha-4 (6-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence 35.3%DLP-114 Alpha-7 (12-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence 44% NCT01786239 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —e NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results14.5%Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 10.4%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 15%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | 1.4%180 mg subcutaneousf NCT03978832 · Phase 4 · registry result, not featured evidence show 22 more results—CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence —CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence —HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence —HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence — NCT01050582 · Phase 4 · registry result, not featured evidence 1.3% NCT01855074 · Phase 4 · registry result, not featured evidence 0% NCT00299702 · Phase 4 · registry result, not featured evidence —PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence —PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence — NCT00056498 · Phase 4 · registry result, not featured evidence 1.7%120 mg NCT02109562 · Phase 3 · registry result, not featured evidence 0%90 mg NCT02109562 · Phase 3 · registry result, not featured evidence —4 mg NCT04567524 · Phase 2 · registry result, not featured evidence 0%4 mg NCT04567524 · Phase 2 · registry result, not featured evidence —2 mg NCT04567524 · Phase 2 · registry result, not featured evidence 0%2 mg NCT04567524 · Phase 2 · registry result, not featured evidence —120 mg NCT01677377 · Phase 2 · registry result, not featured evidence —90 mg NCT01677377 · Phase 2 · registry result, not featured evidence —60 mg NCT01677377 · Phase 2 · registry result, not featured evidence —DLP-114 Alpha-4 (6-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence —DLP-114 Alpha-7 (12-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence — NCT01786239 · Phase na · registry result, not featured evidence |
| Serious AEs | 0.7%e NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results—Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.3%Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 4%Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.3%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 2.7%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 14.3%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 7.1%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | 4.3%180 mg subcutaneousf NCT03978832 · Phase 4 · registry result, not featured evidence show 22 more results18.8%CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 8.3%CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 8.3%HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 0%HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 0% NCT01050582 · Phase 4 · registry result, not featured evidence 1.3% NCT01855074 · Phase 4 · registry result, not featured evidence 17.3% NCT00299702 · Phase 4 · registry result, not featured evidence 4%PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 3.1%PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 3.3% NCT00056498 · Phase 4 · registry result, not featured evidence 0.9%120 mg NCT02109562 · Phase 3 · registry result, not featured evidence 0%90 mg NCT02109562 · Phase 3 · registry result, not featured evidence 0%4 mg NCT04567524 · Phase 2 · registry result, not featured evidence —4 mg NCT04567524 · Phase 2 · registry result, not featured evidence 0%2 mg NCT04567524 · Phase 2 · registry result, not featured evidence —2 mg NCT04567524 · Phase 2 · registry result, not featured evidence 6.7%120 mg NCT01677377 · Phase 2 · registry result, not featured evidence 0%90 mg NCT01677377 · Phase 2 · registry result, not featured evidence 0%60 mg NCT01677377 · Phase 2 · registry result, not featured evidence 0%DLP-114 Alpha-4 (6-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence 7.1%DLP-114 Alpha-7 (12-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence 0% NCT01786239 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | e headache 20.3% (placebo 19.7%) dizziness 17% (placebo 7.5%) sedation 12.7% (placebo 8.2%) NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 18 more resultsdizziness 11.6% (placebo 2.7%) somnolence 8.3% (placebo 0%) dry mouth 6.8% (placebo 0%) NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 dizziness 2.6% (placebo 2.7%) headache 2% (placebo 3.3%) insomnia 2% (placebo 4.7%) NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 dry mouth 17.9% dizziness 17.5% somnolence 14.2% NCT01207414 · Phase 4 · registry result, not featured evidence dizziness 22.3% dry mouth 20.8% insomnia 9.6% NCT01207414 · Phase 4 · registry result, not featured evidence 625 mg injection site pain 66.7% injection site induration 60% injection site swelling 20% NCT01348100 · Phase 1/2 · registry result, not featured evidence 625 mg headache 20% nasal congestion 20% anxiety 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 500 mg injection site pain 60% injection site induration 26.7% injection site swelling 20% NCT01348100 · Phase 1/2 · registry result, not featured evidence 500 mg nasal congestion 33.3% constipation 13.3% somnolence 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg back pain 7.1% constipation 7.1% headache 7.1% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg insomnia 20% headache 13.3% somnolence 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg constipation 14.3% headache 14.3% anxiety 7.1% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg headache 33.3% insomnia 33.3% dyspepsia 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg injection site pain 53.3% headache 26.7% nasal congestion 26.7% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg nasal congestion 40% headache 26.7% oropharyngeal pain 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 125 mg pruritus 50% throat irritation 50% upper respiratory tract infection 50% NCT01348100 · Phase 1/2 · registry result, not featured evidence 125 mg constipation 50% agitation 0% akathisia 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence 50 mg blood creatine phosphokinase increased 50% agitation 0% akathisia 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence 50 mg dizziness 50% headache 50% agitation 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence | 180 mg subcutaneousf upper respiratory tract infection 13% blood prolactin increased 8.7% decreased appetite 8.7% NCT03978832 · Phase 4 · registry result, not featured evidence show 18 more resultsbmi increase normal/overweight to obese 31.3% ldl or triglyceride increase 25% prolactin related symptom 12.5% NCT00333177 · Phase 4 · registry result, not featured evidence bmi increase normal/overweight to obese 25% prolactin related symptom 16.7% ldl or triglyceride increase 8.3% NCT00333177 · Phase 4 · registry result, not featured evidence ldl or triglyceride increase 41.7% prolactin related symptom 16.7% bmi increase normal/overweight to obese 0% NCT00333177 · Phase 4 · registry result, not featured evidence bmi increase normal/overweight to obese 12.5% ldl or triglyceride increase 6.3% prolactin related symptom 6.3% NCT00333177 · Phase 4 · registry result, not featured evidence blood prolactin increased 0.8% drug ineffective 0.8% eye infection 0.8% NCT01050582 · Phase 4 · registry result, not featured evidence extrapyramidal disorder 1.3% NCT01855074 · Phase 4 · registry result, not featured evidence insomnia 26.3% tremor 21.8% anxiety 17.9% NCT00299702 · Phase 4 · registry result, not featured evidence constipation 9.1% insomnia 9.1% somnolence 8.1% NCT00535132 · Phase 4 · registry result, not featured evidence insomnia 9.2% headache 8.2% constipation 6.1% NCT00535132 · Phase 4 · registry result, not featured evidence 120 mg injection site pain 22.2% (placebo 19.5%) headache 15.4% (placebo 23.7%) weight increased 12.8% (placebo 3.4%) NCT02109562 · Phase 3 · registry result, not featured evidence 90 mg headache 17.4% (placebo 23.7%) injection site pain 15.7% (placebo 19.5%) weight increased 13% (placebo 3.4%) NCT02109562 · Phase 3 · registry result, not featured evidence 4 mg akathisia 25% diarrhoea 25% abdominal discomfort 0% NCT04567524 · Phase 2 · registry result, not featured evidence 2 mg alanine aminotransferase increased 25% weight increased 25% abdominal discomfort 0% NCT04567524 · Phase 2 · registry result, not featured evidence 120 mg cough 20% dyspepsia 20% weight increased 20% NCT01677377 · Phase 2 · registry result, not featured evidence 90 mg weight increased 33.3% headache 20% dyspepsia 13.3% NCT01677377 · Phase 2 · registry result, not featured evidence 60 mg weight increased 26.7% headache 20% rash 20% NCT01677377 · Phase 2 · registry result, not featured evidence arthralgia 21.4% weight increased 21.4% abdominal pain 14.3% NCT04418466 · Phase 1/2 · registry result, not featured evidence insomnia 21.4% implant site pain 14.3% injection site discomfort 14.3% NCT04418466 · Phase 1/2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 4.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- ePopulation comparability has not been reviewed for 21 of these studies.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Iloperidone (Fanapt)
show 1 more result
show 3 more results
Risperidone (Risperdal)
+ 22 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (Fanapt)'s landscape · Risperidone (Risperdal)'s landscape